Fairmount Fund Sells $133.5M in Apogee Therapeutics Shares, Reducing Stake

summarizeZusammenfassung

Fairmount Healthcare Fund II L.P., a significant institutional investor with managing members serving on Apogee Therapeutics' board, executed a substantial block trade, selling 1,750,000 shares of common stock for approximately $133.5 million. This sale represents a notable reduction in their overall position, decreasing their beneficial ownership to 9.82% of the company's common stock. While the fund remains a major shareholder, such a large disposition by a key institutional investor, especially one with board representation, could be interpreted by the market as a signal of reduced conviction or a strategic portfolio adjustment.

check_boxSchlusselereignisse

• Significant Share Sale by Institutional Investor

  Fairmount Healthcare Fund II L.P. sold 1,750,000 shares of Apogee Therapeutics common stock in a block trade on January 22, 2026.

• Substantial Transaction Value

  The shares were sold at $76.30 per share, totaling approximately $133.5 million.

• Reduced Ownership Stake

  Following the sale, Fairmount Healthcare Fund II L.P. and its affiliates now beneficially own 9.82% of Apogee Therapeutics' common stock, down from a previous stake of approximately 12.71%.

• Board Representation

  Peter Harwin and Tomas Kiselak, managing members of Fairmount Funds Management LLC, also serve on Apogee Therapeutics' board of directors.

auto_awesomeAnalyse

Fairmount Healthcare Fund II L.P., a significant institutional investor with managing members serving on Apogee Therapeutics' board, executed a substantial block trade, selling 1,750,000 shares of common stock for approximately $133.5 million. This sale represents a notable reduction in their overall position, decreasing their beneficial ownership to 9.82% of the company's common stock. While the fund remains a major shareholder, such a large disposition by a key institutional investor, especially one with board representation, could be interpreted by the market as a signal of reduced conviction or a strategic portfolio adjustment.